Overview

Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC

Status:
RECRUITING

Trial end date:
2026-03-24

Target enrollment:

Participant gender:

Summary

This study aims to explore the efficacy and safety of Crizotinb or Standard Chemotherapy in Met exon 14 skipping Advanced Non-small Cell Lung Cancer

Phase:

PHASE2

Details

Lead Sponsor:

Hunan Province Tumor Hospital

Treatments:

1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
Bevacizumab
Carboplatin
Crizotinib
Immune Checkpoint Inhibitors
Pemetrexed